首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Oncologist

Oncologist杂志,由AlphaMed Press出版,于1996年创刊,Monthly,出版语言English,ISSN:1083-7159,E-ISSN:1549-490X。

投稿咨询
Oncologist
Oncologist
Oncologist
SCI SCIE

杂志介绍

JCR分区
Q2
中科院分区
2区
影响因子
4.7
CiteScore
6.8
期刊收录
SCI、SCIE

Oncologist(中文译名:《肿瘤学家》),ISSN:1083-7159,EISSN:1549-490X,是AlphaMed Press出版的国际性学术期刊,创刊于1996年,以Monthly形式稳定发行,2026年总发文量约376篇。该刊采用非OA开放访问,学科归属为医学 - 肿瘤学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达4.7,2025年期刊CiteScore为6.8,2025年期刊自引率约2.1%,在中科院期刊分区体系中位列医学大类2区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Oncologist长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期一般,3-8周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USACHINA MAINLAND、Italy、France、Spain、Japan、GERMANY (FED REP GER)等为核心发文国家与地区;HARVARD UNIVERSITYMASSACHUSETTS GENERAL HOSPITAL、UNIVERSITY OF TEXAS SYSTEM、DANA-FARBER CANCER INSTITUTE、UNIVERSITY OF CALIFORNIA SYSTEM、MEMORIAL SLOAN KETTERING CANCER CENTER、MAYO CLINIC等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
2区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
2区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
2区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q2 97 / 333

71

学科:ONCOLOGY SCIE Q2 102 / 333

69.52

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q2 89 / 328

73

学科:ONCOLOGY SCIE Q2 87 / 328

73.63


中国学者近期发文

1
Lenvatinib combined with immune checkpoint inhibitors for unresectable, recurrent, or metastatic hepatocellular carcinoma: a real-world stud

Author:Kong, Huifang; Chen, Yan; Li, Hong; Wang, Di; Chang, Xiujuan; Zeng, Zhen; Zhang, Wei

Journal: ONCOLOGIST. 2026; Vol. 31, Issue 5, pp. -. DOI: 10.1093/oncolo/oyag097

2
Dynamic cytogenetic evolution in multiple myeloma: prognostic implications from diagnosis to first relaps

Author:Chen, Qi; Tian, Tian; Shi, Yu; Shen, Xuxing; Qiu, Hairong; Jin, Yuanyuan; Chen, Lijuan; Guo, Rui

Journal: ONCOLOGIST. 2026; Vol. 31, Issue 5, pp. -. DOI: 10.1093/oncolo/oyag105

3
Low opinion of generic oral anticancer drugs: an unacknowledged factor resulting in medication waste in Chin

Author:Wang, Yan; Song, Hongwei; Cao, Jinming; Chen, Zhicong; Xu, Feng

Journal: ONCOLOGIST. 2026; Vol. 31, Issue 5, pp. -. DOI: 10.1093/oncolo/oyag057

4
Association of IDH1 mutations with survival and recurrence in resected intrahepatic cholangiocarcinoma received or not received adjuvant chemotherap

Author:Wang, Pengcheng; Li, Ning; Ye, Yuhang; Pu, Jing; Sun, Rongqi; Luo, Chubin; Hu, Zhiqiang; Zhou, Zhengjun; Li, Jia; Zou, Jixue; Fan, Jia; Zhou, Jian; Zhou, Shaolai

Journal: ONCOLOGIST. 2026; Vol. 31, Issue 5, pp. -. DOI: 10.1093/oncolo/oyag124

5
Treatment strategies for small cell carcinoma of the esophagus: comparative analysis of multimodal regimens in two independent real-world cohort

Author:Yin, Xiaolei; Li, Xiaopeng; Mi, Lili; Hou, Jiaojiao; Yin, Fei

Journal: ONCOLOGIST. 2026; Vol. 31, Issue 5, pp. -. DOI: 10.1093/oncolo/oyag115

6
The efficacy of sequential radiotherapy after the combination of TACE with lenvatinib and anti-PD-1 antibodies for unresectable HC

Author:Ou, Xiangye; Li, Jinhai; Pan, Rongjian; Liu, Deyi; Wu, Jiayi; Liang, Dong; Li, Yinan; Zeng, Zhenxin; Li, Han; Zhang, Yuxuan; Wu, Junyi; Yan, Maolin

Journal: ONCOLOGIST. 2026; Vol. 31, Issue 5, pp. -. DOI: 10.1093/oncolo/oyag138

7
Predictive modeling of treatment-related thyroid dysfunction and prognostic implication in advanced nasopharyngeal carcinoma with PD-1 inhibitor

Author:Hu, Yubin; Hong, Xinyi; Li, Yi; Zhang, Honghong; Warsi, Mohammad Abidullah; Chen, Ronghui; Lin, Chaoying; Ou, Peidong; Lin, Cuibo; Qiu, Sufang

Journal: ONCOLOGIST. 2026; Vol. 31, Issue 4, pp. -. DOI: 10.1093/oncolo/oyag066

8
Construction of a predictive model based on the risk of relapse after cytarabine consolidation therapy in acute myeloid leukemia patient

Author:Ji, Min; Hao, Yiping; Li, Wei; Zhou, Ying; Jia, Ruinan; Li, Wei; Jin, Shumin; Dai, Min; Chang, Mengyuan; Feng, Lei; Liu, Tingting; Zhang, Di; Ji, Chunyan; Ye, Jingjing

Journal: ONCOLOGIST. 2026; Vol. 31, Issue 4, pp. -. DOI: 10.1093/oncolo/oyag088

9
Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella stud

Author:Manji, Gulam A.; Chung, Vincent; Oh, Do-Youn; Lacy, Jill; Lopez, Charles D.; Ponz-Sarvise, Mariano; Macarulla, Teresa; Thomas, Roby; George, Ben; Alistar, Angela; Siveke, Jens T.; Xu, Yun; Lau, Janet; Cha, Edward; Kim, Kyu-Pyo; O'Reilly, Eileen M

Journal: ONCOLOGIST. 2026; Vol. 31, Issue 4, pp. -. DOI: 10.1093/oncolo/oyag023

10
A prospective post-marketing observational study of abemaciclib in patients with HR+, HER2-breast cancer in Chin

Author:Ouyang, Quchang; Yuan, Peng; Liu, Jianxia; Teng, Yuee; Li, Zhihua; Ji, Xuening; Liu, Lina; Wang, Mopei; Zou, Liqun; Xu, Ling; Yang, Suisheng; Zhu, Zhenxin; Yang, Liu; Li, Jinnan; Liu, Qiang

Journal: ONCOLOGIST. 2026; Vol. 31, Issue 4, pp. -. DOI: 10.1093/oncolo/oyag013


在线咨询

Oncologist

国际简称:ONCOLOGIST参考译名:肿瘤学家

年发文量:376 CiteScore:6.8 是否预警:否 Gold OA文章占比:99.80% 研究类文章占比:85.64%

杂志社联系方式:ALPHAMED PRESS, 318 BLACKWELL ST, STE 260, DURHAM, USA, NC, 27701-2884

Oncologist